In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Approach To Sourcing Innovation: Closing The Networking Gap

Executive Summary

Johnson & Johnson is nearing the completion of its network of early-stage innovation centers. IN VIVO talks to Patrick Verheyen of the year-old London hub to see where innovation centers fit into the J&J plan, and to Jimmy Zhang of the company’s soon-to-launch Shanghai branch about the climate for innovation in China and the wider Asia-Pacific region.

You may also be interested in...



GSK Woes Raise Big Pharma R&D Question

GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.

Bioqube Takes The Reins At J&J Innovation's JLINX

The recently launched venture capital firm has partnered with J&J Innovation to manage its new European life sciences incubator. START-UP speaks with bioqube's managing partner Nico Vandervelpen.

Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future Business Models

Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV004271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel